| 19th Mar 2026 7:10 am |
MFN |
Faron Pharmaceuticals Ltd: Director Dealing |
| 19th Mar 2026 7:05 am |
MFN |
Faron Pharmaceuticals Ltd: Director Dealing |
| 19th Mar 2026 7:00 am |
MFN |
Faron Pharmaceuticals Ltd: Director Dealing |
| 12th Mar 2026 2:30 pm |
RNS |
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY |
| 12th Mar 2026 2:30 pm |
MFN |
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY |
| 11th Mar 2026 6:20 pm |
RNS |
The Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus |
| 11th Mar 2026 6:20 pm |
MFN |
The Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus |
| 11th Mar 2026 8:00 am |
RNS |
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY |
| 10th Mar 2026 7:48 am |
RNS |
Inside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway |
| 10th Mar 2026 7:48 am |
MFN |
Inside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway |
| 9th Mar 2026 5:45 pm |
MFN |
Update to Faron's Financial Calendar and date of the Annual General Meeting in 2026 |
| 4th Mar 2026 4:45 pm |
MFN |
Correction: Faron Pharmaceuticals Ltd's Annual Report 2025 published |
| 4th Mar 2026 7:15 am |
MFN |
Faron Pharmaceuticals Ltd's Annual Report 2025 published |
| 4th Mar 2026 7:00 am |
MFN |
Faron's Financial Statements Release 1 January to 31 December 2025 |
| 2nd Mar 2026 10:00 am |
MFN |
Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting |
| 9th Feb 2026 5:45 pm |
MFN |
Faron Pharmaceuticals Ltd: NOTICE TO THE EXTRAORDINARY GENERAL MEETING |
| 9th Feb 2026 5:35 pm |
MFN |
Inside Information: Faron Pharmaceuticals Ltd is planning a rights offering of approximately EUR 40 million to strengthen its capital structure and to drive lead asset bexmarilimab to key milestones |
| 3rd Feb 2026 4:00 pm |
MFN |
Faron Pharmaceuticals Ltd: Registration of New Shares |
| 3rd Feb 2026 7:00 am |
MFN |
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds |
| 13th Jan 2026 4:00 pm |
MFN |
Faron Pharmaceuticals Ltd: PDMR Dealing |
| 8th Jan 2026 5:45 pm |
MFN |
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds |
| 17th Dec 2025 2:30 pm |
MFN |
Composition of Faron Pharmaceutical's Shareholders' Nomination Board |
| 11th Dec 2025 8:30 am |
MFN |
Faron issues second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement |
| 4th Dec 2025 4:00 pm |
MFN |
Faron Pharmaceuticals Ltd: Holding(s) in Company |
| 3rd Dec 2025 10:00 am |
MFN |
Faron Pharmaceuticals Ltd: Registration of New Shares |
| 3rd Dec 2025 7:00 am |
MFN |
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds |
| 2nd Dec 2025 7:00 am |
MFN |
Faron Pharmaceuticals Ltd: Grant of Options |
| 1st Dec 2025 7:00 am |
MFN |
Faron Pharmaceuticals Ltd: Appointment of CFO |
| 27th Nov 2025 7:00 am |
MFN |
Faron's Financial Calendar for 2026 |
| 20th Oct 2025 6:00 am |
MFN |
Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients |
| 3rd Oct 2025 10:00 am |
MFN |
Faron Pharmaceuticals Ltd: Registration of New Shares |
| 3rd Oct 2025 6:00 am |
MFN |
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds |
| 19th Sep 2025 6:00 am |
MFN |
Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of Equity |
| 12th Sep 2025 3:25 pm |
MFN |
Correction: FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY - 30 JUNE 2025 |
| 27th Aug 2025 6:00 am |
MFN |
FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY - 30 JUNE 2025 |
| 19th Aug 2025 6:00 am |
MFN |
Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results |
| 18th Aug 2025 6:00 am |
MFN |
Inside Information: Faron to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA |
| 8th Aug 2025 2:00 pm |
MFN |
Faron Pharmaceuticals Ltd: Holding(s) in Company |
| 7th Aug 2025 6:00 am |
MFN |
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds |
| 6th Aug 2025 6:00 am |
MFN |
Inside Information: Faron to present updated BEXMAB data in frontline HR-MDS to FDA; complete remission rate substantially increased to 43% |
